The once-daily oral drug is intended to enhance the effects of donepezil (Pfizer and Eisai’s off-patent Aricept), with pivotal trial results expected in October this year. This will be easier to ...

Use of donepezil (Aricept), an acetylcholinesterase inhibitor, for 3 weeks failed to demonstrate efficacy in treating fatigue ...